...and the rest

The Mail on Sunday

Shares in Texas-based “predictive analytics” business Spectral MD have leapt on news that it will delist from Aim and move to the US Nasdaq as part of a “complex takeover deal”. The firm’s DeepView tool offers hospitals a “sophisticated” means to determine “whether wounds will heal on their own or require specialist help”. Perplexity about the details of the deal have left the shares on a substantial discount to the offer price. Existing shareholders “should sit tight and await developments” (44p).

Shares

Laboratory landlord Life Science Reit offers investors exposure to the niche but worldleading British life-sciences scene. On a 33% discount to the most recent available net asset value (NAV) and yielding a prospective 6.5% the shares are still a buy (62p).

The Telegraph

FTSE 100 packaging company Smurfit Kappa offers a “potent mix of capital growth and income potential”. Its 100% renewable product lines are an advantage in a time of growing environmental awareness. Packaging is “not the most riveting” way to invest your money, but “interesting companies do not necessarily make for sound investments”.

Buy (2,952p).

The Times

Polymer maker Victrex has had a tough few years. The firm makes Peek, a “strong, light and resilient plastic material used in cars... medical implants, mobile phones [and] industrial machinery”. The material taps into “mega-trends” such as fuel-efficiency and population ageing, but rival materials do exist. Nevertheless, the shares are “worth a punt” at this level (1,556p).